Back to news 
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
CATALIS Honors Louise Proulx at the Conclusion of Her Term on the Board of Directors
Governance, Recent news
14 October 2025
In this article
Share
CATALIS wishes to express its gratitude and acknowledge the end of Ms. Louise Proulx’s term as a member of the Board of Directors and Chair of the Audit and Risk Management Committee.
An active member of the Board since 2018, Ms. Proulx has played a key role in strengthening the organization’s strategic governance. Through her rigor, vision, and dedication, she has made an outstanding contribution to establishing CATALIS as a key player in Quebec’s clinical research ecosystem.
A Message From Me Jean Groleau, Chair of the Board of Directors
“The Board of Directors has greatly benefited from Louise’s commitment and strategic vision. She has made a remarkable contribution to the solid foundation on which CATALIS stands today.”
Me Jean Groleau
Lawyer and co-founder
Groleau Gauthier Plante LLP
The Board of Directors of CATALIS brings together experts from Quebec’s healthcare institutions, the pharmaceutical industry, and independent directors. Together, they ensure sound governance and guide CATALIS’ key priorities, in line with its mission to optimize the clinical research environment and accelerate the development of innovative treatments for patients in Quebec.
Mr. Jean Groleau, Chair of the Board of Directors, along with all board members, wishes to sincerely thank Ms. Proulx for her exemplary leadership, generosity, and invaluable contribution to CATALIS’ mission.
Her departure marks the conclusion of a mandate characterized by collaboration, excellence, and dedication, leaving a lasting impact on the organization’s governance.
